Nektar Therapeutics revenue
Nektar Therapeutics's revenue was $55.2m in fiscal 2025, down 43.9% on the year before. Since fiscal 2009 ($71.9m) it has grown at a compound -1.6% a year. Over the last twelve months it was $54.6m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72 | 159 | 71 | 81 | 149 | 201 | 231 | 165 | 308 | 1,193 | 115 | 153 | 102 | 92 | 90 | 98 | 55 | 55 |
| Growth on the year before | — | +121.1% | −55.1% | +13.6% | +83.4% | +34.8% | +15.0% | −28.3% | +86.0% | +287.8% | −90.4% | +33.4% | −33.4% | −9.7% | −2.1% | +9.2% | −43.9% | — |
| Gross profit | — | — | — | — | — | — | — | 135 | 277 | 1,169 | 93 | 133 | 77 | 70 | 56 | 68 | 55 | — |
| Gross margin | — | — | — | — | — | — | — | 81.7% | 90.1% | 98.0% | 81.4% | 87.3% | 75.6% | 76.5% | 62.5% | 68.8% | 100.0% | — |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Non Cash Royalty Revenue Related To Sale of Future Royalties | $54.9M | 99.5% | ▼ 14.5% |
| Non Cash Royalties (part of Non Cash Royalty Revenue Related To Sale of Future Royalties) | $54.9M | 99.9% | ▼ 14.6% |
| Products (part of Non Cash Royalty Revenue Related To Sale of Future Royalties) | $0 | 0.0% | ▼ 100.0% |
| License Collaboration and Other Revenue | $300,000 | 0.5% | ▼ 49.7% |
From Nektar Therapeutics's 10-K filed March 13, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Nektar Therapeutics | $54.6m | -27.2% | -14.6% |
| Tango Therapeutics, Inc. | $53.8m | 121.5% | 16.9% |
| Siga Technologies Inc | $53.7m | -70.1% | -18.1% |
| Gossamer Bio, Inc. | $53.3m | 32.4% | — |
| Ocular Therapeutix, Inc | $52.1m | -8.1% | -1.6% |
| Invivyd, Inc. | $58.4m | 26.3% | — |
Compare with peers
- Tango Therapeutics, Inc. revenue
- Siga Technologies Inc revenue
- Gossamer Bio, Inc. revenue
- Ocular Therapeutix, Inc revenue
- Invivyd, Inc. revenue
Head to head: NKTR vs TNGXNKTR vs SIGAGOSS vs NKTRIVVD vs NKTR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies